You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
Kedrion Biosc - Front Image


  1. 27-11-2018

    Results as of 30 September 2018

    Consolidated turnover of Euro 438.6 million and adjusted EBITDA of Euro 104.8 million

    read more 
  2. 07-09-2018

    First half results 2018

    Consolidated turnover of Euro 278.3 million and adjusted gross margin of 39.0%

    read more 
  3. 17-07-2018

    Updated Bylaws

    Kedrion’s Extraordinary Meeting of Shareholders approves the amendment of the Company’s Bylaws

    read more 
  4. 28-05-2018

    Shareholders’ Agreement

    Sestant Internazionale, Sestant and FSI Investimenti sign a new Shareholders’ Agreement concerning Kedrion

    read more 
  5. 22-05-2018

    FY 2017 Results General Investor Call

    Friday 25 May 2018 – 09.00 GMT / 10.00 CET

    read more 
  6. 27-04-2018

    Annual General Meeting of Shareholders 2018

    Kedrion’s shareholders approve financial statements for fiscal year 2017, confirm board of directors

    read more 
  7. 29-03-2018

    Annual Results 2017

    Consolidated turnover of Euro 602.5 million and adjusted EBITDA of Euro 139.9 million, up 31.6%

    read more 
  8. 31-10-2017

    Kedrion and Cerus enter distribution agreement for INTERCEPT in Italy

    Agreement covers complete INTERCEPT product line: platelets, plasma, and red blood cells

    read more 
  9. 25-08-2017

    Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®

    The product is approved for post-exposure prophylaxis against rabies infection

    read more 


For more information please contact: